Does Blue Cross and Blue Shield of Illinois cover Mounjaro?

BCBS Illinois covers Mounjaro, but only with prior authorization.

Blue Cross and Blue Shield of Illinois covers Mounjaro (tirzepatide) for type 2 diabetes on its 2026 commercial drug list, with prior authorization and quantity limits. The prior authorization criteria require that the patient has already tried an antidiabetic agent, so a first-line drug like metformin usually comes first. BCBSIL will not cover Mounjaro for weight loss. Tirzepatide for weight management is sold as Zepbound, which BCBSIL lists separately and covers only when the employer group elects an anti-obesity benefit. This is per BCBSIL Prior Authorization/Step Therapy Program, GLP-1 Agonists, July 2026, verified August 27, 2026.

Coverage at a glance

IndicationCoverage
Type 2 diabetesCovered with prior authorization

Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.

Coverage by indication

Type 2 diabetes · Covered with prior authorization
Step therapy

What the prior authorization needs:

  • Prior authorization required. The GLP-1 agonists program covers Mounjaro when it is used per FDA-approved labeling and dosing.
  • Step therapy applies. Approval requires a prior trial of an antidiabetic agent, typically metformin, before Mounjaro.
  • Quantity limit of 4 pens per 28 days for the 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths, and 4 pens per 180 days for the 2.5 mg starter strength, per the July 2026 Multi-Tier Basic Annual Drug List (https://www.bcbsil.com/il/documents/rx-drugs/drug-lists/multi-basic-annual-il-2026.pdf).
  • Listed as a covered brand on the July 2026 drug list. The exact payment tier depends on the member benefit design, since this list does not print a per-drug tier and excludes non-preferred drugs.
  • Not covered for weight loss. Zepbound is the tirzepatide product for weight management and is listed separately, subject to its own prior authorization and an employer-elected anti-obesity benefit.

Policy 23466.0726. Source: BCBSIL Prior Authorization/Step Therapy Program, GLP-1 Agonists, July 2026. pa_policy. Verified August 27, 2026.

What to do next

If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.

  • Browse the prior-authorization letter library for a template that matches your plan and indication.
  • Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
  • If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
  • If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.

What it costs without insurance

The programs below bill you directly. Prices checked every Monday.

Frequently asked questions

Does BCBS Illinois cover Mounjaro?

Blue Cross and Blue Shield of Illinois covers Mounjaro (tirzepatide) for type 2 diabetes on its 2026 commercial drug list, with prior authorization and quantity limits. The prior authorization criteria require that the patient has already tried an antidiabetic agent, so a first-line drug like metformin usually comes first. BCBSIL will not cover Mounjaro for weight loss. Tirzepatide for weight management is sold as Zepbound, which BCBSIL lists separately and covers only when the employer group elects an anti-obesity benefit. This reflects the published policy verified August 2026.

What does BCBS Illinois require to approve Mounjaro?

For type 2 diabetes: true

Coverage for other payers

See the full payer coverage index for every plan we have sourced.

Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.

This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.